Starting January 1, 2025, the Inflation Reduction Act eliminated the coverage gap (donut hole) and capped out-of-pocket drug costs at $2,000 per year under CMS IRA Part D Redesign
The increase in fiscal 2023 as compared to fiscal 2022 was primarily attributable to an increase in licensing costs of $7,500,000 associated with the CSPC License Agreement and $2,325,000 associated with the achievement of two development milestones under the UCSF License Agreement, as well as increases of $4,317,000 in manufacturing costs associated with the production and testing of CRB-601, $3,041,000 in pre-clinical and clinical costs to advance our pipeline to prepare for the start of clinical trials, and $1,309,000 in consulting and temporary employee costs to support various areas of regulatory, quality, manufacturing, and clinical operations
After adjusting for differences such as age, sex, ethnicity, body mass index and other illnesses, they found that people on GLP-1 drugs had a 37 per cent higher risk of alopecia than those taking SGLT-2 inhibitors and a 68 per cent higher risk than those on DPP-4 inhibitors
Caron, A., Richard, D
Wanting, Gut-Brain Axis (01:52:03) Tool: Sugar vs
